Home › Pulmonary Arterial Hypertension › NCT06872112

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Phase I Study: A Dose-Escalation Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Who can join

Ages 18 to 60 · All sexes

Inclusion Criteria

* Each participant must meet the following criteria to be enrolled in this study:
* Adults aged 18 to 75 years.
* WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.

Exclusion Criteria

* Participants who meet any of the following criteria will be excluded from the study.
* Participants with serious concomitant morbidity per investigator assessment.

About the study

This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.

What is being tested

• Artesunate (drug)

Sponsor: Joseph C. Wu · Participants: 15 · Started: Apr 1, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT06872112

Locations in the U.S.

Conditions

• Pulmonary Arterial Hypertension

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.